Inozyme Pharma, Inc. (INZY) |
|
4.67 0.18 (4.01%)
|
09-27 11:13 |
|
Open: |
4.73 |
Pre. Close: |
4.49 |
|
High:
|
4.95 |
Low:
|
4.665 |
|
Volume:
|
299,121 |
Market Cap:
|
288(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:47:38 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 6.09 One year: 7.12 |
| Support: |
Support1: 4.42 Support2: 3.94 |
| Resistance: |
Resistance1: 5.21 Resistance2: 6.09 |
| Pivot: |
4.55  |
| Moving Average: |
MA(5): 4.55 MA(20): 4.63
MA(100): 5.48 MA(250): 3.83 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 47 %D(3): 43.7 |
| RSI: |
RSI(14): 51.1 |
| 52-week: |
High: 7.32 Low: 0.99 |
| Average Vol(K): |
3-Month: 697 (K) 10-Days: 975 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INZY ] has closed below upper band by 29.3%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.84 - 4.87 |
4.87 - 4.9 |
|
Low:
|
3.88 - 3.91 |
3.91 - 3.94 |
|
Close:
|
4.44 - 4.49 |
4.49 - 4.53 |
|
Company Description |
|
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. |
Headline News |
Wed, 27 Sep 2023
Inozyme Pharma (NASDAQ:INZY) Rating Reiterated by Needham ... - MarketBeat
Tue, 26 Sep 2023
Why Inozyme Pharma (INZY) Stock Is Trading Higher Today - Inozyme Pharma (NASDAQ:INZY) - Benzinga
Tue, 26 Sep 2023
Is Inozyme Pharma Inc (INZY) Stock a Good Value Tuesday? - InvestorsObserver
Tue, 26 Sep 2023
China and US Strengthen Economic Dialogue and Cooperation - Best Stocks
Sat, 09 Sep 2023
Wedbush Reaffirms Outperform Rating for Inozyme Pharma ... - MarketBeat
Wed, 06 Sep 2023
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
62 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
0.9 (%) |
|
% Held by Institutions
|
84.8 (%) |
|
Shares Short
|
1,690 (K) |
|
Shares Short P.Month
|
1,830 (K) |
Stock Financials |
|
EPS
|
-1.42 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.27 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.5 |
|
Return on Equity (ttm)
|
-53.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.15 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-62 (M) |
|
Levered Free Cash Flow
|
-36 (M) |
Stock Valuations |
|
PE Ratio
|
-3.35 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
2.08 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.72 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
